Page 1 | Search Results | Blood | American Society of Hematology

Skip to Main Content

Skip Nav Destination

1-3 of 3

Sort by

Sort Order Select

Journal Articles

Long-term follow-up with sustained progression-free survival (PFS) benefit after subcutaneous (SC) mosunetuzumab in combination with polatuzumab vedotin compared with rituximab plus polatuzumab vedotin in patients with relapsed or refractory (R/R) B-cell non-Hodgkin lymphoma

Nilanjan Ghosh, Julio Chavez, Mariana Bastos-Oreiro, Catherine Diefenbach, Izidore S. Lossos, Nirav Shah, Sarit Assouline, Adam Olszewski, Seema Naik, Song Pham, Michael C. Wei, Connie L. Batlevi, Iris To, Wahib S. Ead, Sneha Makadia, Elicia Peneul, Elizabeth Budde

Blood (2025) 146 (Supplement 1): 1020.

https://doi.org/10.1182/blood-2025-1020

Published: 2025

Journal Articles

Fixed-duration intravenous mosunetuzumab plus polatuzumab vedotin combination therapy continues to demonstrate durable responses in patients with large B-cell lymphoma: 3-year follow-up from a Phase Ib/II study

Manali Kamdar, Julio Chavez, Adam Olszewski, Sarit Assouline, Izidore S. Lossos, Catherine Diefenbach, Dipenkumar Modi, Waleed Sabry, Seema Naik, Amitkumar Mehta, Sneha Makadia, Song Pham, Elicia Peneul, Hao Wu, Wahib S. Ead, Iris To, Dennis J. Houston, Connie Lee Batlevi, Elizabeth Budde

Blood (2025) 146 (Supplement 1): 3735.

https://doi.org/10.1182/blood-2025-3735

Published: 2025

Journal Articles

A Randomized Phase II Study of Mosunetuzumab SC Plus Polatuzumab Vedotin Demonstrates Improved Outcomes Versus Rituximab Plus Polatuzumab Vedotin in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)

Blood (2024) 144 (Supplement 1): 989.

https://doi.org/10.1182/blood-2024-194581

Published: 2024